The Application of a Three-Step Proteome Analysis for Identification of New Biomarkers of Pancreatic Cancer by Abulaizi, Mayinuer et al.
Hindawi Publishing Corporation
International Journal of Proteomics
Volume 2011, Article ID 628787, 13 pages
doi:10.1155/2011/628787
Research Article
The Application of a Three-Step Proteome Analysis for
Identiﬁcation of New Biomarkers of Pancreatic Cancer
Mayinuer Abulaizi,1,2 Takeshi Tomonaga,1,3 Mamoru Satoh,1,2 KazuyukiSogawa,1,2
Kazuyuki Matsushita,1,2 Yoshio Kodera,2,4 Jurat Obul,1 Shigetsugu Takano,5
Hideyuki Yoshitomi,5 MasaruMiyazaki,5 andFumioNomura1,2
1Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
2Clinical Proteomics Research Center, Chiba University Hospital, Chiba 260-8677, Japan
3Laboratory of Proteome Research, National Institute of Biomedical Innovation, Osaka 567-0085, Japan
4Laboratory of Biomolecular Dynamics, Department of Physics, Kitasato University School of Science, Sagamihara 252-0373, Japan
5Department of General Surgery, Graduate School of Medicine, Chiba University, 260-8670 Chiba, Japan
Correspondence should be addressed to Mayinuer Abulaizi, ablizmaynur@gmail.com
Received 31 May 2011; Accepted 2 August 2011
Academic Editor: Tadashi Kondo
Copyright © 2011 Mayinuer Abulaizi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We searched for novel tumor markers of pancreatic cancer by three-step serum proteome analysis. Twelve serum abundant
proteins were depleted using immunoaﬃnity columns followed by fractionation by reverse-phase high-performance liquid
chromatography. Proteins in each fraction were separated by two-dimensional gel electrophoresis. Then the gel was stained by
Coomassie Brilliant Blue. Protein spots in which the expression levels were signiﬁcantly diﬀerent between cancer and normal
control were identiﬁed by LC-MS/MS. One hundred and two spots were upregulated, and 84 spots were downregulated in
serum samples obtained from patients with pancreatic cancers, and 58 proteins were identiﬁed by mass spectrometry. These
candidate proteins were validated using western blot analysis and enzyme-linked immunosorbent assay (ELISA). As a result of
thesevalidationprocess,wecouldconﬁrmthattheserumlevelsofapolipoproteinA-IV,vitaminD-bindingprotein,plasmaretinol-
binding protein 4, and tetranectin were signiﬁcantly decreased in patients with pancreatic cancer.
1.Introduction
Pancreaticcancerisoneofthemostlethalmalignancies,with
a5 - y e a rs u r v i v a lr a t eo fo n l y4 - 5 %[ 1]. The major reasons
for the poor prognosis may be late diagnosis and limited
therapeutic options; early diagnosis of pancreatic cancer is
a pressing clinical problem.
Serum levels of the conventional tumor markers includ-
ing carcinoembryonic antigen (CEA) and the Lewis blood
group carbohydrate antigen (CA19-9) often remain in nor-
mal range at early stages of this malignancy [2]. Therefore,
search for novel biomarkers of pancreatic cancer is needed.
Recent advances in proteomic technologies have pro-
vided promising ways to discover and identify novel bio-
markersinvariousﬁeldsofclinicalmedicine. Althoughthere
has been long and uncertain path from marker discovery to
clinical utility [3], sophisticated technologies have facilitated
the discovery of potential tumor markers with improved
sensitivities and speciﬁcities for the diagnosis of cancer
patients [4]. Also, proteome analysis can lead to biomarkers
that may be useful in the prediction of clinical response to
anticancer therapy [5].
Surface enhanced laser desorption/ionization time-of-
ﬂight mass spectrometry (SELDI-TOF MS) is a represen-
tative example of a proteomics technique for the high-
throughput ﬁngerprinting of serum proteins and peptides
andbiomarkerdiscovery[6].Usingthistechnology,wecould
detect and identify novel diagnostic markers for alcohol
abuse [7] and also a new prognostic marker for pancreatic
cancer [8].
Oneofthetechnicalchallengesinserumproteomeanaly-
sis is that serum contains thousands of proteins and peptides2 International Journal of Proteomics
thatarepresentinalargedynamicconcentration[9].Indeed,
22 abundant proteins such as albumin, immunoglobulins,
and transferring constitute up to 99% of the protein content
of plasma [10]. In proteomic studies searching for low-
abundance serum proteins or peptides, depletion of those
abundant proteins and further fractionation of samples will
be necessary.
We recently conducted a three-step proteome analysis
involving removal of 12 abundant proteins and subsequent
reversed-phase high-performance liquid chromatography
fractionation and one-dimensional electrophoresis: we suc-
cessfully identiﬁed three proteins including YKL-50 as a
promising biomarker of sepsis [11].
Proteomics in pancreatic cancer research including ser-
um or plasma biomarker search has been reviewed [12]. A
three-step approach as-we used in this study has not been
tried in biomarker search for pancreatic cancers before.
Inthisstudy,weappliedthisthree-stepproteomeanalysis
to ﬁnd novel biomarkers of pancreatic cancer.
2. Method
2.1. Patients Studied. Serum samples were obtained preop-
eratively from a total of 32 patients diagnosed with primary
invasive pancreatic ductal carcinoma who had surgery at the
Department of General Surgery, Chiba University Hospital.
Clinical data of 32 patients are summarized in Table 1(a).
Serum samples were also obtained from apparently healthy
and age-matched subjects who had medical checkup at
the Port-square Kashiwado Clinic, Kashiwado Memorial
Foundation (Table 1(b)). All samples were frozen by liquid
nitrogen and were stored at −80◦C until analysis. Written
informed consent was obtained from all the subjects. The
ethics committee of our institute approved the protocol.
2.2. A Three-Step Serum Proteome Analysis
2.2.1. Immunoaﬃnity Subtraction of Highly Abundant Pro-
teins from Human Serum. Serum samples obtained from
4 patients with pancreatic cancer (Nos 1∼4i nTable 1(a))
were pooled. Sera obtained from 4 age-matched healthy
volunteers were also pooled (Nos 1∼4i nTable 1(b)). As the
ﬁrst step of proteome analysis, the twelve most abundant
proteins (albumin, Immunoglobulin G, transferrin, ﬁbrino-
gen, Immunoglobulin A, Immunoglobulin M, apolipopro-
tein A-I, apolipoprotein A-II, haptoglobin, α1-acid glyco-
protein and α2-macroglobulin) were removed from serum
by passage through a commercially available immunoaﬃnity
column, the ProteomeLab IgY12HC LC10 (Beckman coulter,
Inc. Fullerton, CA. USA.) Ninety microliters of each pooled
sample was subjected to the immunoaﬃnity subtraction as
we previously described [11]. The combined ﬂow-through
fractions were concentrated by Vivaspin2 spin concentrators
(molecular weight cutoﬀ, 10kDa, Vivascience, Hannover,
Germany) and were stored at −80◦C until use.
In addition, sera from 32 patients with pancreatic cancer
and 32 healthy volunteers were used for validation. Eight
healthy controls and 8 of relatively advanced cases (Nos 1∼8
in Tables 1(a) and 1(b)) were chosen for ﬁrst validation and
24 of them (Nos 9∼32 in Tables 1(a) and 1(b)) were used for
the second validation experiment.
2.3. HPLC Separation of Immunoaﬃnity-Subtracted Serum
Samples. Immunoaﬃnity-subtracted serum samples pre-
pared as described above were separated by reverse-phase
HPLC in an automated HPLC system, the SHISEIDO
Nanospace SI-2 (Shiseido Fine Chemicals, Tokyo, Japan)
essentially as we described before [11]. A total of 40 fractions
were collected at 0.5min intervals from 19.6 to 39.6min.
Each fraction was immediately lyophilized by a centrifugal
vacuum concentrator and stored at −80◦C until further
analysis.
2.4. Two-Dimensional Gel Electrophoresis. The IEF gels
(70mm length, Inner 2.5mm diameter and pH ranges from
3 to 10) were prepared as previously described [13, 14]. The
lyophilized samples (from fraction 6 to fraction 25) were
dissolved with 15μL sample preparation buﬀer and proteins
were separated by two-dimensional gel electrophoresis with
agarose gels in the ﬁrst dimension as described by Oh-Ishi
et al. [13].
2.5. In-Gel Digestion and LC-MS/MS. CBB stained 2-DE
imagesof pooled serumsamplesobtained frompatients with
pancreatic cancer were compared with those obtained from
healthy volunteers. Diﬀerentially expressed protein bands
were excised from the gel and were subjected to in-gel tryptic
digestion as previously reported [14]. Digested peptides
were injected into a trap column: 0.3 × 5mm L-trap column
(Chemicals Evaluation and Research Institute, Saitama,
Japan) and an analytical column: 0.1 × 50mm Monolith
column(AMR,Tokyo,Japan),whichwasattachedtoaHPLC
system (Nanospace SI-2; Shiseido Fine Chemicals, Tokyo,
Japan). The ﬂow rate of a mobile phase was 1μL/min. The
solvent composition of the mobile phase was programmed
to change in 35min cycles with varying mixing ratios of
solvent A (2%v/v CH3CN and 0.1%v/v HCOOH) to solvent
B (90%v/v CH3CN and 0.1%v/v HCOOH): 5–50% B
20min, 50–95% B 1min, 95% B 3min, 95–5% B 1min, 5%
B 10min. Puriﬁed peptides were introduced from HPLC
to an LTQ-XL (Thermo Scientiﬁc, CA, USA), an ion trap
mass spectrometer (ITMS), via an attached Pico Tip (New
Objective, MA, USA). The MS and MS/MS peptide spectra
were measured in a data-dependent manner according to
the manufacturer’s operating speciﬁcations. The Mascot
search engine (Matrixscience, London, UK) was used to
identify proteins from the mass and tandem mass spectra
of peptides. Peptide mass data were matched by searching
the Human International Protein Index database (IPI, July
2008, 72079 entries, European Bioinformatics Institute)
using the MASCOT engine. The minimum criterion of the
probability-based MASCOT/MOWSE score was set with 5%
as the signiﬁcant threshold level. When the candidates had
SEQUESTscoreslowerthan100orwhentheSEQEUSTscore
was computed by using fewer than one peptides fragment,
we inspected the raw MS and MS/MS spectra of peptides
to judge their qualities (see Figures a–f in Supplementary
Material available online at doi: 10.1155/2011/628787).International Journal of Proteomics 3
Table 1
(a) Clinical features of pancreatic cancer patients.
No Gender Age (years) UICC-stage Tumor size (mm) TP (g/dL) ALB (g/dL) Che (U/L) T-Cho (mg/dL)
1 M 66 III 35 6.7 4.3 270 220
2 M 66 III 39 6.6 4.4 359 198
3 M 79 IV 10 6.2 3.8 179 155
4 M 71 III 18 6.8 4.0 207 210
5 M 65 III 35 7.0 3.7 189 131
6 M 78 III 50 6.6 4.4 359 198
7 M 66 IIA 30 6.3 4.1 267 176
8 M 62 IV 10 5.9 3.6 171 169
9 M 38 IA 10 6.7 4.0 289 179
10 M 50 IB 30 7.3 4.6 408 203
11 M 63 IIA 18 6.6 3.9 260 138
12 M 62 IIA 38 6.0 3.4 124 149
13 M 54 IIA 24 7.0 4.5 198 162
14 M 73 IIA 25 6.7 4.1 242 176
15 F 76 IIA 26 5.0 3.3 162 95
16 M 63 IIB 15 7.1 4.2 175 163
17 M 65 IIB 32 5.8 3.5 227 113
18 M 68 IIB 80 6.8 4.0 316 217
19 M 71 IIB 24 7.5 4.1 221 144
20 M 74 IIB 27 7.0 4.3 319 178
21 F 68 IIB 27 6.5 4.0 223 177
22 M 63 IIB 26 6.9 4.3 262 219
23 F 68 IIB 27 6.1 3.5 339 163
24 M 61 IIB 30 6.2 4.0 200 176
25 F 74 IIB 40 6.6 3.8 221 170
26 M 62 IIB 60 8.3 3.5 140 155
27 F 73 IIB 35 5.9 3.2 130 169
28 F 59 IIB 18 7.2 4.4 356 130
29 M 73 IIB 50 5.7 3.3 127 135
30 F 62 IIB 25 6.8 4.1 255 293
31 F 71 III 25 6.8 4.2 294 159
32 F 78 III 50 5.9 3.3 197 182
Ave ± SD 66 ±8.63 0 .9 ±15.06 .6 ±0.63 .9 ±0.4 240.2 ± 75.6 171.9 ±6.6
UICC: international union against cancer, M: male, F: female. TP: total protein. ALB: albumin. Che: cholinesterase. T-Cho: total cholesterol. Ave:
average. SD: standard deviation.
From number 1 to 4 were used for 2-DE, from number 1 to 8 were for ﬁrst western blot, from number 9 to 32 were for second western blot.
(b) Clinical features of healthy controls.
No Gender Age (years) TP (g/dL) ALB (g/dL) Che (U/L) T-Cho (mg/dL)
1 M 62 7.5 4.7 401 203
2 M 61 7.7 5.1 396 269
3 M 64 7.2 4.4 284 229
4 M 73 7.6 4.7 216 203
5 M 57 8.3 5.0 430 301
6 M 57 6.7 4.8 328 253
7 M 65 7.2 4.8 375 230
8 M 64 7.2 4.6 327 2964 International Journal of Proteomics
(b) Continued.
No Gender Age (years) TP (g/dL) ALB (g/dL) Che (U/L) T-Cho (mg/dL)
9 M 55 6.9 4.6 300 211
10 M 71 7.1 4.7 290 267
11 F 64 8.1 5.4 293 192
12 M 71 7.2 4.5 233 213
13 M 55 7.2 4.5 365 227
14 M 68 7.4 4.4 300 255
15 F 67 7.0 4.5 279 172
16 F 71 7.0 4.5 297 220
17 M 60 6.7 4.2 284 183
18 M 61 7.0 4.7 260 198
19 M 55 6.4 3.9 304 176
20 F 70 7.6 4.7 398 225
21 M 70 7.3 4.6 257 250
22 F 67 7.4 4.5 304 194
23 M 60 7.0 4.4 338 234
24 F 77 8.1 5.0 416 274
25 F 62 7.5 4.6 284 169
26 F 64 7.2 4.5 280 208
27 M 65 7.4 4.6 264 231
28 M 61 7.8 4.3 319 239
29 M 61 7.3 4.6 309 271
30 M 66 7.5 5.0 375 278
31 F 65 7.6 4.5 339 288
32 M 73 7.1 4.4 306 211
Ave ± SD 64.4 ±5.77 .3 ±0.44 .6 ±0.3 317 ±53.4 230.3 ±36.9
M: male, F: female. TP: total protein. ALB: albumin. Che: cholinesterase. T-Cho: total cholesterol. Ave: average. SD: standard deviation.
From number 1 to 4 were used for 2-0E, from number 1 to 8 were for ﬁrst western blot, from number 9 to 32 were for second western blot.
2.6. Western Blot Analysis. Western blotting was performed
as we previously described [15].
Brieﬂy, immunoaﬃnity-subtracted serum samples were
separated on SDS-PAGE in 10–20% polyacrylamide gra-
dient gel (DRC, Tokyo, Japan) and were transferred to
polyvinylidene ﬂuoride membranes (0.45μm thickness, Mil-
lipore, Bedford, MA) at 10V for overnight. The following
antibodies commerciallyavailablewereusedasprimaryanti-
bodies; mouse anti-human ApoA-IV antibody (BML Inc.,
Tokyo, Japan), mouse anti-human GC antibody (LifeSpan,
Inc., UK), mouse monoclonal anti-human RBP4 antibody
(Abnova.Com., Taipei, Taiwan) and mouse anti-human
CLEC3B antibody (BioPorto, Grusbakken 8, DK-2820 Gen-
tofte, Denmark). Antigens on the membrane were detected
with enhanced chemiluminescence detection reagents (GE
Healthcare). Band intensities of the western blot images
were quantiﬁed by TotalLab TL12 imaging analysis software
(Shimadzu Co., Ltd. Kyoto, Japan) and were presented by
arbitrary units.
2.7.OtherProcedures. Inaddition towesternblotting,ELISA
was conducted in some marker candidates using human
ApoA-IV ELISA kit (Millipore, Missouri, USA), GC ELISA
kit (immundiagnostik AG, Bensheim), and RBP4 ELISA
kit; (R & D systems). Their optical density was measured
at 450nm using a microplate reader (iMark Microplate
Reader S/N 10288). Serum levels of CEA and CA19-9 were
determined by established commercially available kits.
2.8. Statistical Analysis. Statistical analysis was conducted
using KaleidaGraph 4.0J (Synergy Software, Reading, PA)
and IBM SPSS Statistics 18 (SPSS Inc., IL, USA). Signiﬁcance
was deﬁned as P<0.05.
3. Results
3.1. Discovery and Identiﬁcation of Diﬀerentially Expressed
Proteins by a Three-Step Proteome Analysis. To discover
and identify novel serum markers for pancreatic cancer,
we employed a comparative three-step proteome analysis
of the pooled serum samples obtained from patients with
pancreatic cancer and healthy volunteers. As the ﬁrst step, 12
abundant proteins were removed by immunosubtractions.
The immunoaﬃnity-subtracted samples were separated byInternational Journal of Proteomics 5
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Figure 1: Comparison of 2-DE images of the same fraction of
healthy volunteer control and pancreatic cancer patient sample.
Electrophoresis was performed on the same gel and at the same
condition. Figure 1 is an example of Coomassie blue-stained gel
displayingspotsfromdepletedandfractionatedserumfromcontrol
(left, n = 4, pooled) and pancreatic cancer patients (right, n =
4, pooled). (Fraction number is 10th). Double circles indicate
increased spot in pancreatic cancer. Single circle indicates decreased
spot in pancreatic cancer.
RP-HPLC, and 20 fractions (fractions Nos 6–25) were
subjected to 2-DE. A representative example is shown in
Figure 1. By comparing the 2-DE images of the proteins
included in the 20 fractions, a total 186 spots were found
to be diﬀerently expressed. Subsequent LC-MS/MS could
identify 100 proteins. Excluding keratins, complements and
trypsin, 58 proteins were selected; 37 of them were upregu-
lated and 21 were downregulated (Tables 2(a) and 2(b)).
3.2.ValidationofMarkerCandidatesbyWesternBlotting. Out
of the 58 proteins listed in Tables 2(a) and 2(b), we focused
on 19 proteins the alterations of which at serum level have
not been studied in detail before, and also antibodies to be
used for validation studies are available. Initial validation
was conducted using 8 serum samples (nos. 1–8 in Table 1)
obtained from relatively advanced cases with pancreatic
cancer including the four cases used for the three-step
analysis. Western blotting of the 19 proteins indicated in
Tables 2(a) and 2(b) revealed that expression of 7 proteins
were found to be signiﬁcantly decreased in patients with
pancreatic cancers compared with controls: they were inter-
alpha trypsin inhibitor heavy chain H1 (ITIH1), hemopexin
precursor (HPX), alpha-1B-glycoprotein precursor (A1BG),
apolipoprotein A-IV precursor (ApoA-IV), vitamin D-
binding protein precursor (GC), plasma retinol-binding
protein precursor (RBP4), and tetranectin (CLEC3B).
We then conducted the second validation study to test
whether diﬀerential expression of the 7 protein candidates
described above is reproducible using another set of serum
samples obtained from 24 patients with pancreatic cancers
including cases with relatively early stages (nos. 9–32 in
Table 1(a)). As shown in Figure 2(a) the expression levels
of the four proteins ApoA-IV, GC, RBP4, and CLEC3B
were greater in cancer patients than in controls. The diﬀer-
ences were statistically signiﬁcant assessed by densitometry
Figure 2(b).
3.3. Validation of Marker Candidates by ELISA. ELISA kits
were commercially available for GC, ApoA-IV, and RBP4.
Their serum levels were determined in the 15 pairs of serum
samples obtained from relatively early stages of patients used
for the second validation by western blotting. Serum ApoA-
IV levels of patients with pancreatic cancer (107.8±99.9A U)
were signiﬁcantly lower than those in healthy volunteers
(195.2 ± 66.9A U, P = 0.008) Figure 3(a).G Cl e v e l sw e r e
signiﬁcantly lower in the patient group with pancreatic
cancer (25.4 ± 10UA) when compared with healthy group
(34.3 ± 10.3A U , P = 0.03) Figure 3(b).A l s o ,s e r u mR B P
levels in the patients (43.0 ±5.9AU) were signiﬁcantly lower
than in the controls (50.2 ±4.2, P = 0.0004) Figure 3(c).
3.4. Comparison of the Marker Candidates with CEA and
CA19-9. Figure 4showsthereceiver-operatingcharacteristic
curve (ROC) analysis for the three marker candidates
determined by ELISA and those for CEA and CA19-9. The
areas under the curves for ApoA-IV, GC, RBP4, CA19-9,
and CEA were 0.79, 0.72, 0.85, 0.88, 0.58, 0.88, 0.89, and
0.89, respectively. Also, AUCs of the combination assay of
GC/CA19-9, ApoA-IV/CA19-9, and RBP/CA19-9 were 0.88,
0.89, and 0.89, respectively.
In Tables 3(a)and 3(b),serumlevels ofApoA-IV, GC and
RBP4 determined by ELISA are listed together with CEA and
CA19-9. Therewere7casesinwhichserumCA19-9levelwas
not elevated. Out of these 7 cases, ApoA-IV levels were below
the lower reference interval value (mean SD) in 2 cases. Also,
GClevelswerebelowthelowerreferenceintervalvalueinone
case.
4. Discussion
The sequencing of the human genome has opened the door
for comprehensive analysis of all the messenger RNA (tran-
scriptome) and proteins (proteome). Messenger RNA con-
centrations, however, are not necessarily predictive of cor-
responding protein concentrations. Indeed, a recent report
indicatesthatthesharingratebetweencDNAmicroarrayand
proteome-based proﬁlings is limited for the identiﬁcation of
candidatebiomarkersinrenalcellcarcinoma[16].Therefore,
proteome analysis is one of the prerequisite for development
of novel biomarkers. Proteomic studies in pancreatic cancers
have been conducted by many research groups as reviewed
[12, 17]. Hwang et al. found by using 2-DE/MS that phos-
phoglycerate kinase (PGK) 1, a secretable glycolytic enzyme
involved in angiogenesis, is overexpressed in serum samples
of pancreatic cancer patients, as compared to controls [18].
More recently, using the two-dimensional image-converted
analysis of liquid chromatography and mass spectrometry
(2DICAL) and a “glyco capturing” through concanavalin A-
agarose, Ono et al. identiﬁed a novel prolyl-hydroxylation
of ﬁbrinogen alpha chain in plasma samples obtained from
patients with pancreatic cancers [19].6 International Journal of Proteomics
Table 2
(a) Proteins upregulated in pancreatic cancer.
Protein’s name Experimental Theoretical Score(1) Queries Validation
mass (Da) mass (Da) matched(2)
Histidine-rich glycoprotein precursor 80000 59541 150 3 WB(3)
Plasminogen precursor 100000 90510 331 8
IGHM protein 50000 52754 105 2
TF Serotransferrin precursor 75000 77000 601 14 WB
Isoform LMW of Kininogen-1 precursor 70000 47853 242 6
F2 Prothrombin precursor (Fragment) 90000 69992 486 8
Alpha-1B-glycoprotein precursor 43000 54239 590 8 WB
Vitronectin precursor 62000 54271 581 8 WB
Hepatocyte growth factor-like protein precursor 85000 80268 284 6 WB
Plasma kallikrein precursor 90000 71323 246 8
Ceruloplasmin precursor 115000 122128 1452 49
Isoform 1 of Ficolin-3 precursor 34400 32883 58 1
Transthyretin precursor 95000 15877 4489 13
Serum amyloid P-component precursor 24000 25371 2293 12
Antithrombin III variant 61000 52658 1984 20
SERPINC1 protein 61000 29074 1147 11
Carbonic anhydrase 1 30800 28852 679 10 WB
Isoform 1 of C-reactive protein precursor 26000 25023 169 6
Apolipoprotein A-1 31600 30759 225 4
Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H3 138000 75031 529 12
Leucine-rich alpha-2-glycoprotein precursor 47000 38154 549 8
Isoform 1 of N-acetylmuramoyl-L-alanine amidase precursor 68900 67957 193 4
Xaa-Pro dipeptidase 53700 54513 144 3
Inter-alpha (globulin) inhibitor H4 130500 103261 1242 26 WB
Vitamin K-dependent protein S precursor 84000 75074 136 4 WB
Serpin peptidase inhibitor, clade D (Heparin cofactor), 72000 57034 374 9
Isoform 1 of Fibronectin precursor 200000 262442 553 14 WB
Alpha-1-antichymotrypsin precursor 62800 50566 3315 33 WB
Kallistatin precursor 59600 48511 123 2
Plastin-2 72000 70245 215 5
Corticosteroid-binding globulin precursor 62500 45112 52 1
Myosin-1 31600 222976 96 2
Isoform 1 of Serum albumin precursor 73000 69321 261 9
Cholinesterase precursor 83000 72836 50 1
AMBP protein precursor 200000 38974 68 1
Plasma protease C1 inhibitor precursor 87000 55119 1168 15
Apolipoprotein B-100 precursor 300000 515241 3982 117
(1)MOWSE score of candidate proteins.
(2)Number of peptide fragments yielding informative MS/MS.
(3)WB: western blot.
(b) Proteins downregulated in pancreatic cancer.
Protein’s name Experimental Theoretical Score(1) Queries Validation
mass (Da) mass (Da) matched(2)
Plasma retinol-binding protein precursor 19000 22995 373 8 WB(3)
Coagulation factor XII precursor 75000 67774 140 5
Tetranectin precursor 19000 22552 61 1 WB
Hyaluronan-binding protein 2 precursor 68000 62630 195 6International Journal of Proteomics 7
(b) Continued.
Protein’s name Experimental Theoretical Score(1) Queries Validation
mass (Da) mass (Da) matched(2)
Vitamin D-binding protein precursor 55000 52883 284 14 WB
Hemopexin precursor 75000 51643 635 8 WB
Lumican precursor 100000 38405 120 6 WB
Isoform 1 of Gelsolin precursor 80000 85644 1360 23 WB
Afamin precursor 80000 69024 307 7
Carboxypeptidase N catalytic chain precursor 49000 52253 244 12 WB
Inter-alpha-trypsin inhibitor heavy chain H1 precursor 200000 101326 812 13 WB
Histone H4 25700 11360 59 1
JUP JUP protein 100000 81675 90 3
apolipoprotein A-IV precursor 42000 45371 2188 35 WB
Inter-alpha-trypsin inhibitor heavy chain H2 precursor 200000 106370 1636 26 WB
Pigment epithelium-derived factor precursor 50000 46313 529 11
Angiotensinogen precursor 56300 53121 986 13
SERPINF2 protein 58000 55029 75 2
Actin, cytoplasmic 1 100000 41710 208 5
Thrombospondin-1 precursor 175000 129300 152 4
Alpha-2-macroglobulin precursor 180000 163175 559 18
(1)MOWSE score of candidate proteins.
(2)Number of peptide fragments yielding informative MS/MS data. The minimum signiﬁcant threshold level of the probability-based MASCOT/MOWSE
score was set at 5%.
(3)WB: western blot.
In this study, the three-step procedure was carried out to
discover novel markers of pancreatic cancer. The outline of
the three-step procedures is shown in Figure 5.
Asaﬁrststep,serumsamplesweresubjectedtoantibody-
based immunoaﬃnity column that simultaneously removes
12abundantserumproteins.Theconcentratedﬂow-through
was then fractionated using reversed-phase HPLC. Proteins
obtained in each HPLC fraction were further separated by
2-DE. A total of 58 diﬀerentially expressed proteins were
identiﬁed. As results of initial validation by western blotting
in relatively advanced cases and further validation including
the less advanced cases by western blotting, the expression
levels of the four proteins ApoA-IV, GC, RBP4, and CLEC3B
were greater in cancer patients than in controls. Out of these
four proteins, ELISA were available in apolipoprotein A-IV,
retinol-binding protein precursor (RBP4), and vitamin D
binding protein (GC). Serum levels of these 3 proteins were
signiﬁcantly lower in patients with pancreatic cancer than
in healthy volunteers. In ROC analyses, the area under the
curves for these three proteins was not signiﬁcantly greater
than that for CA19-9, but it is noteworthy that among the
4 cases of pancreatic cancers in which serum levels of both
CEA and CA19-9 were within the reference intervals, at least
one of ApoA-IV, RBP4, and GC was found to be decreased
in 2 cases, suggesting that these candidate markers could be
complementary to the conventional markers in diagnosis of
pancreatic cancer.
ApoA-IV is present in human intestinal epithelial cells
and is secreted as a chylomicron and VLDL apoprotein [20].
Retinol binding protein 4 (RBP4) is a 21-kDa protein
synthesized in the liver and adipose tissue; its major function
is to deliver retinol to tissue [21]. Fabris et al. determined
serum RBP levels in patients with pancreatic cancer and
found that the levels decreased concomitant with zinc
and prealbumin levels [22]. Serum zinc levels were not
signiﬁcantly correlated with RBP4 levels in the present study
(data not shown).
Vitamin D-binding protein is a plasma protein involved
in vitamin D transport and other function. Although
diagnostic role of this protein in pancreas cancer has not
been reported yet, inhibitory role of vitamin D binding
protein-macrophage activating factor (DBP-maf) in
pancreatic carcinogenesis has been pointed out [23].
Tetranectinbindstokringle4ofplasminogen,enhancing
the plasminogen activation by tissue-type plasminogen acti-
vator in the presence of poly-D-lysine [24] Low serum levels
of tetranectin (CLEC3B) are associated with increased risk of
second-line chemoresistance in patients with ovarian cancer
[25]. Also, in colorectal cancer, signiﬁcantly shorter survival
was found for patients with CLEC3B levels below a cut-oﬀ
point of compared to patients with levels above [26].
Thus, the results of this study show that four serum
proteins, apolipoprotein A-IV, vitamin D binding protein,
retinol-binding protein 4, and tetranectin are signiﬁcantly8 International Journal of Proteomics
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Figure 2: (a) Magniﬁed views of 2-D gel images and western blotting analysis of ApoA-IV, GC, plasma retinol binding protein 4 RBP4, and
CLEC3B in serum samples. Coomassie blue-stained 2-D gel images from pooled control and pancreatic cancer displaying the protein spots
for ApoA-IV, GC, RBP4, and CLEC3B are shown in left panels (a1), (a2), (a3) and (a4). Western blotting of these four proteins are shown
in the right panel (b1), (b2), (b3) and (b4). (b) Quantitation of diﬀerentially expressed serum proteins in pancreatic cancer and healthy
volunteers by Western blot analysis. Intensities of each band were calculated by TotalLab TL 120 software. Closed circles indicate healthy
volunteers and closed squares indicate patients with pancreatic cancer. Signiﬁcance of the diﬀerences were calculated by using Wilcoxon
Mann-Whitney test. Panel A: ApoA-IV levels of serum were signiﬁcantly lower in the depleted sera of pancreatic cancer when compared
wi t ht h ed e p l e t e ds e r ao fh e a l t h yv o l u n t e e r s( P<0.0001). Panel (B, C and D) are for proteins GC, RBP4, and CLEC3B and their serum levels
were likewise lower in the pancreatic cancer patients. Their P values are lower than 0.0001, 0.001, and 0.009, respectively.International Journal of Proteomics 9
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Figure 3: Quantitation of diﬀerentially expressed proteins in pancreatic cancer by ELISA. ELISA was performed using human ApoA-IV
ELISA kit vitamin D binding protein ELISA kit and RBP4 ELISA kit, in serum samples obtained from 15 patients with pancreatic cancers
and 15 control subjects. Analysis was performed by using Wilcoxon Mann-Whitney test. Closed circles indicate control and closed squares
indicate cancer. (a): ApoA-IV levels of serum of patient with pancreatic cancer group (107.76 ± 25.8AU) were lower than those in healthy
group (185.27 ± 16.0A U ,P = 0.01); (b): GC levels were signiﬁcantly lower in the patient group with pancreatic cancer (25.35 ± 9.8U A)
when compared with healthy group (34.40±10.2A U ,P = 0.03); (c): RBP4 levels were lower in the pancreatic cancer group (42.99±1.5A U)
than healthy group (50.7 ±1.00AU, P<0.001).
decreased in patients with pancreatic cancer. It was notable
that these changes were observed in some patients in whom
conventional tumor markers for this malignancy were not
altered.
The reasons why serum levels of these proteins were
decreased in pancreatic cancer patients are not clear at the
moment.Itisunlikelythatthealterationswereentirelydueto
malnutrition because serum levels of the 4 proteins were not
signiﬁcantly correlated with their serum albumin levels. It is
possiblethatsomenegativemediatorsoriginatedfromtumor
and/or the cancer-tissue microenvironments were regulating
their production. It is unlikely that the alterations were due
to biliary obstruction because the extent of the alterations
of the four markers were not related to the extent of biliary
obstruction (data not shown). Alterations of these four
proteinsinchronicpancreatitisaswellasbiliarytractdiseases
remain to be studied. Also, it remains to be determined
whether serum levels of these four proteins are changed in
other gastroenterological cancers.
Although exact mechanisms responsible for the reduc-
tion remain to be investigated, alterations of serum levels of
apolipoprotein A-IV, vitamin D binding protein, tetranectin,
and retinol binding protein may have complementary role in
diagnosis of pancreas cancer.10 International Journal of Proteomics
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Figure 4: Receiver operating characteristic (ROC) curves for CA19-9, CEA, ApoA-IV, GC, RBP4 Their AUCs are described in the text.International Journal of Proteomics 11
Table 3
(a) Serum tumor marker levels in patients with pancreatic cancer.
Gender Age (years) UICC-stage Tumor size
(mm)
CA19-9
(U/mL)
CEA
(ng/mL) ApoA-IV (AU) GC (AU) RBP4 (AU)
M 38 IA 10 26.2 2.3 262.1 35.9 54.2
M 50 IB 30 46.5 2.3 8.5 34.3 43.9
M 63 IIA 18 157 1.1 10.2 26.7 37.0
M∗ 62 IIA 38 9 5 70.7 25.1 41.5
M∗ 54 IIA 24 11 1.4 87.5 11.3 42.5
M 73 IIA 25 15.5 3.5 203.5 13.6 49.5
F∗ 76 IIA 26 13.3 1.5 70.7 33.1 43.2
M 65 IIB 32 1579 3.4 352.1 24.3 36.7
M∗ 74 IIB 27 10.9 3.4 0 28.0 35.3
F 74 IIB 40 43 3.2 54 25.8 38.9
F 68 IIB 27 302 2.1 82.8 40.8 36.4
M 61 IIB 30 10 1.4 134.7 27.3 46.2
M 63 IIB 15 1080 — 144.6 23.9 53.3
M∗ 73 IIB 50 13.9 2.1 23.2 1.8 43.1
F 62 IIB 25 11.5 1.1 111.7 28.4 43.1
Ave ± SD 63.7 ±10 .42 7 .8 ±9.9 221.9 ±466.26 3 .7 ±10.4 107.8 ±99.92 5 .4 ±10 50.2 ±4.2
CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protein, RBP4: plasma retinol
binding protein 4.
The stars indicate the patient who had a normal CA19-9 level and a low ApoA-IV.
Ave:average. SD: standard deviation. AU: arbitrary unit.
(b) Serum tumor marker levels in healthy controls.
Gender Age (years) CA19-9 (u/mL) CEA (ng/mL) ApoA-IV (AU) GC (AU) RBP4 (AU)
M 71 33.9 2.2 157.4 29.5 47.7
M 55 0.1 4.7 243.8 35.0 48.5
M 55 6.4 1 223.0 35.3 54.3
M 55 0.1 3.5 237.1 33.0 48.1
M 60 7.7 0.8 237.1 23.9 44.1
M 60 37.4 7 214.0 39.6 48.8
M 61 7.6 4.8 277.0 16.8 49.7
F 77 7.1 1.1 294.5 24.2 43.7
M 61 7.8 1.3 80.6 33.4 55.3
F 61 6 3 210.1 45.8 56.3
F 65 2.9 2.1 65.7 61.7 53.3
M 66 5.1 0.7 156.7 33.8 44.7
F 62 11.7 1.7 122.9 33.0 50.9
F 64 8.4 1.2 222.9 38.7 50.3
F 71 24.4 2.6 184.7 30.5 56.3
Ave ± SD 62.9 ±6.31 1 .1 ±11.52 .5 ±1.8 195.2 ±66.93 4 .3 ±10.35 0 .2 ±4.2
CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protien, RBP4: plasma retinol
binding protein
Ave: average. SD: standard deviation. AU: arbitrary unit.12 International Journal of Proteomics
(4 pancreatic cancer, 4 healthy volunteers)
Western blot and ELISA
Three-step proteome analysis
Immunodepletion of 12 major proteins (Beckman column)
40 fractionation (reversed-phase HPLC)
Agarose 2-DE/CBB staining
In-gel digestion, LC-MS/MS analysis
Serum 90µL
Figure 5: Outline of the procedure for the three-step serum
proteome analysis.
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